Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + vinorelbine
- Development stage
- Phase 2
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apatinib + vinorelbine is a combination therapy consisting of apatinib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2), and vinorelbine, a semisynthetic vinca alkaloid. Apatinib works by blocking angiogenesis through VEGFR-2 inhibition, while vinorelbine primarily inhibits metaphase mitosis of cancer cells through its interactions with tubulin. This combination has shown efficacy in treating HER2-negative breast cancer and non-driver gene mutation advanced non-small cell lung cancer (NSCLC), particularly in patients who have failed previous treatment regimens.
- Other names
- Apatinib mesylateVinorelbine tartrate
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on apatinib + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + vinorelbine.